<DOC>
	<DOCNO>NCT00369629</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , work different way stop growth cancer cell , either kill cell stop dividing . Pemetrexed disodium may stop growth cancer cell block enzymes need cell growth . Giving gemcitabine together pemetrexed disodium may kill cancer cell . PURPOSE : This planned phase I/II trial study side effect determine best dose gemcitabine hydrochloride give together pemetrexed disodium . Unfortunately , due lack funding , phase II portion never conduct .</brief_summary>
	<brief_title>Gemcitabine Pemetrexed Disodium Treating Patients With Advanced Mycosis Fungoides Sézary Syndrome</brief_title>
	<detailed_description>OBJECTIVES : 1 . Determine safety tolerability gemcitabine hydrochloride pemetrexed disodium patient advance mycosis fungoides Sézary syndrome . ( Phase I ) 2 . Determine maximum tolerate dose gemcitabine hydrochloride administer pemetrexed disodium patient . ( Phase I ) OUTLINE : This phase I , dose-escalation study gemcitabine hydrochloride . Originally , design follow phase II portion determine efficacy population . Unfortunately , due lack funding , phase II portion never conduct . During Phase I : Patients receive pemetrexed disodium IV 10 minute gemcitabine hydrochloride IV day 1 15 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos gemcitabine hydrochloride maximum tolerate dose ( MTD ) determine . The MTD define dose ≥ 2 6 patient experience dose-limiting toxicity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* mycosis fungoides Sézary syndrome Stage IBIVB disease NOTE : *Pathology report must read diagnostic consistent mycosis fungoides/Sézary syndrome Failed ≥ 1 prior systemic treatment Measurable disease At least 1 indicator lesion must designate prior study entry PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 6 month Creatinine ≤ 2.0 mg/dL Creatinine clearance ≥ 45 mL/min Bilirubin ≤ 2.2 mg/dL AST ALT ≤ 2 time upper limit normal WBC ≥ 3,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ No acute infection require systemic treatment No history severe hypersensitivity reaction study drug ingredient use formulation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior topical therapy , systemic chemotherapy , biological therapy No acetylsalicylic acid nonsteroidal antiinflammatory drug ( NSAIDs ) 2 day 2 day pemetrexed disodium infusion ( 5 day 2 day pemetrexed disodium infusion patient take NSAIDs long halflife [ e.g. , naproxen , refocoxib , celecoxib ] ) No concurrent topical agent except emollient No concurrent topical systemic anticancer therapies No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>